Company Profiles

driven by the PitchBook Platform

Glionova Therapeutics

Glionova Therapeutics
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Out of Business LATEST DEAL TYPE
$5.67M TOTAL AMOUNT RAISED
Description

Developer of therapies created to treat cancer. The company's candidate, GLN-1001, is a orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
Västra trädgårdsgatan 15
111 53 Stockholm
Sweden
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Glionova Therapeutics’s full profile, request a free trial.

Glionova Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business $5.67M Completed Out of Business
2. Grant 20-Nov-2014 00000 00.000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 12-Nov-2014 $5.67M $5.67M Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding request access »

Glionova Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Eugen Steiner Ph.D Chief Executive Officer